- Live attenuated vaccines, which use a weakened form of the virus or bacteria to stimulate a strong and long-lasting immune response, are increasingly vital components of immunization programs in both pediatric and adult populations due to their high efficacy and ability to mimic natural infections
- The escalating demand for live attenuated vaccines is primarily fueled by the global rise in infectious diseases, expanded government vaccination initiatives, and growing public awareness about preventive healthcare and immunization
- North America dominated the live attenuated vaccines market with the largest revenue share of 40.01% in 2024, characterized by well-established healthcare infrastructure, high immunization coverage, and strong presence of major pharmaceutical companies, with the U.S. experiencing substantial growth in live attenuated vaccine administration across both public and private healthcare sectors
- Asia-Pacific is expected to be the fastest-growing region in the live attenuated vaccines market during the forecast period, projected to expand at a CAGR of 24.1%, driven by increasing birth rates, expanding government-funded immunization programs, and rising healthcare investments in countries like India and China
- Viral segment dominated the live attenuated vaccines market with a market share of 64.7% in 2024, owing to the high prevalence of viral infections such as measles, mumps, rubella, and polio, and the widespread adoption of viral-based live attenuated vaccines in global immunization programs
